Search Results - "OGER, J"

Evidence for a two-stage disability progression in multiple sclerosis by Leray, Emmanuelle, Yaouanq, Jacqueline, Le Page, Emmanuelle, Coustans, Marc, Laplaud, David, Oger, Joël, Edan, Gilles

“…It is well documented that disability accumulation in multiple sclerosis is correlated with axonal injury and that the extent of axonal injury is correlated…”
Get full text

Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial by GOODIN, D. S, REDER, A. T, KNAPPERTZ, V, EBERS, G. C, CUTTER, G, KREMENCHUTZKY, M, OGER, J, LANGDON, D, RAMETTA, M, BECKMANN, K, DESIMONE, T. M

“…To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal…”
Get full text

Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada by Kingwell, E, van der Kop, M, Zhao, Y, Shirani, A, Zhu, F, Oger, J, Tremlett, H

“…ObjectiveTo examine mortality and factors associated with survival in a population based multiple sclerosis (MS) cohort.MethodsClinical and demographic data of…”
Get full text

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS by FREEDMAN, M. S, BAR-OR, A, FERENCZI, L, VERCO, T, OGER, J, TRABOULSEE, A, PATRY, D, YOUNG, C, OLSSON, T, LI, D, HARTUNG, H.-P, KRANTZ, M

“…To evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (SPMS) who express human leukocyte antigen (HLA)…”
Get full text

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence : Report report of the therapeutics and technology assessment subcommittee of the american academy of neurology by GOODIN, D. S, FROHMAN, E. M, HURWITZ, B, O'CONNOR, P. W, OGER, J. J, REDER, A. T, STEVENS, J. C

“…The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS)…”
Get full text

Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years by MacMillan, EL, Tam, R, Zhao, Y, Vavasour, IM, Li, DKB, Oger, J, Freedman, MS, Kolind, SH, Traboulsee, AL

“…Background: Few biomarkers of progressive multiple sclerosis (MS) are sensitive to change within the two-year time frame of a clinical trial. Objective: To…”
Get full text

Beta-interferon exposure and onset of secondary progressive multiple sclerosis by Zhang, T., Shirani, A., Zhao, Y., Karim, M. E., Gustafson, P., Petkau, J., Evans, C., Kingwell, E., van der Kop, M., Zhu, F., Oger, J., Tremlett, H.

“…Background and purpose Beta‐interferons (IFNβ) are the most widely prescribed drugs for patients with multiple sclerosis (MS). However, whether or not…”
Get full text

‘Clinically definite benign multiple sclerosis’, an unwarranted conceptual hodgepodge: evidence from a 30-year observational study by Leray, E, Coustans, M, Le Page, E, Yaouanq, J, Oger, J, Edan, G

“…Background: Benign multiple sclerosis (BMS) is a controversial concept which is still debated. However identification of this kind of patients is crucial to…”
Get full text

Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis by Laule, C., Vavasour, IM, Zhao, Y., Traboulsee, AL, Oger, J., Vavasour, JD, Mackay, AL, Li, DKB

“…Background: Spinal cord involvement in multiple sclerosis (MS) is common and an important element in disability. Previous studies demonstrated smaller cervical…”
Get full text

High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study by Chan, S, Kingwell, E, Oger, J, Yoshida, E, Tremlett, H

“…Background: Post-marketing studies and case reports have linked beta-interferon (IFNβ) treatment with liver enzyme abnormalities and liver injuries in patients…”
Get full text

Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study by Shirani, A., Zhao, Y., Karim, M. E., Petkau, J., Gustafson, P., Evans, C., Kingwell, E., van der Kop, M. L., Oger, J., Tremlett, H.

“…Background and purpose It was recently reported that there was no significant overall association between interferon beta exposure and disability progression…”
Get full text

Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: Preparation and physicochemical characterization by Elkharraz, K., Faisant, N., Guse, C., Siepmann, F., Arica-Yegin, B., Oger, J.M., Gust, R., Goepferich, A., Benoit, J.P., Siepmann, J.

“…The aim of this study was to prepare different types of paclitaxel-loaded, PLGA-based microparticles and lipidic implants, which can directly be injected into…”
Get full text

Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know by Alkhawajah, Mona M, Caminero, Ana B, Freeman, Hugh J, Oger, Joel JF

“…Multiple sclerosis (MS) is a demyelinating disorder of the central nervous system (CNS) but the causes have not been defined. The disease process appears to…”
Get full text

Longitudinal changes in myelin water fraction in two MS patients with active disease by Vavasour, I.M, Laule, C, Li, D.K.B, Oger, J, Moore, G.R.W, Traboulsee, A, MacKay, A.L

“…Abstract Multiple sclerosis (MS) is characterised by focal areas that undergo cycles of demyelination and remyelination. Although conventional magnetic…”
Get full text

Fulminant liver failure during interferon beta treatment of multiple sclerosis by YOSHIDA, E. M, RASMUSSEN, S. L, STEINBRECHER, U. P, ERB, S. R, SCUDAMORE, C. H, CHUNG, S. W, OGER, J. J, HASHIMOTO, S. A

Get full text

Acetylcholine receptor antibodies in myasthenia gravis are associated with greater risk of diabetes and thyroid disease by Toth, C., McDonald, D., Oger, J., Brownell, K.

“…Objective –  Myasthenia gravis (MG) may be associated with the presence of acetylcholine receptor antibodies (AChRAb) [seropositive MG (SPMG)] or their absence…”
Get full text

A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain by MOORE, G. R. W, LEUNG, E, PATY, D. W, MACKAY, A. L, VAVASOUR, I. M, WHITTALL, K. P, COVER, K. S, LI, D. K. B, HASHIMOTO, S. A, OGER, J, SPRINKLE, T. J

“…To determine the pathologic basis of areas not exhibiting signal of the short-T2 component of the T2 relaxation distribution in MS, as studied in…”
Get full text

Reappraisal of Lhermitte’s sign in multiple sclerosis by Al-Araji, Adnan H, Oger, Joel

“…Lhermitte’s sign (LS) is strongly linked to multiple sclerosis (MS). Our aim is to reassess its frequency, natural history, various characteristics and…”
Get full text

Reduced effectiveness of long-term interferon-β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study by Boz, C., Oger, J., Gibbs, E., Grossberg, S.E.

“…Multiple sclerosis (MS) patients treated with interferon-beta (IFN-β) often form anti-IFN-β antibodies accompanied by a reduction in IFN-β bioavailability. The…”
Get full text

A full genome search in multiple sclerosis by Ebers, George C, Kukay, Kim, Bulman, Dennis E, Sadovnick, Adele D, Rice, George, Anderson, Carol, Armstrong, Holly, Cousin, Keith, Bell, Robert B, Hader, Walter, Paty, Donald W, Hashimoto, Stanley, Oger, Joel, Duquette, Pierre, Warren, Sharon, Gray, Trevor, O'Connor, Paul, Nath, Avindra, Auty, Anthony, Metz, Luanne, Francis, Gordon, Paulseth, John E, Murray, T. John, Pryse-Phillips, William, Nelson, Robert, Freedman, Mark, Brunet, Donald, Bouchard, Jean-Pierre, Hinds, David, Risch, Neil

“…The aetiology of multiple sclerosis (MS) is uncertain. There is strong circumstantial evidence to indicate it is an autoimmune complex trait. Risks for first…”
Get full text